The Tumor Microenvironment and Metastasis (TMM) Program was launched in 2012 to bring together a multidisciplinary team of cutting-edge immunologists and cancer biologists under a synergistic and collaborative scientific umbrella. This initiative provides for the natural evolution of the former Immunology Program that was dissolved at the end of 2011 as part of the strategic reorganization of the Cancer Center. The TMM Program comprises ten investigators with experimental interests aligned along three major flagship themes: Immunoregulation ofthe tumor microenvironment (i); Pathophysiology of metastasis (ii); and Bi-directional interaction between tumor and non-cancerous cells and their products (iii). The overarching goal of the TMM Program is to merge basic mechanistic understanding of multidisciplinary pathways of host-tumor interactions and metastatic dissemination with novel translational opportunities for disease diagnosis and (immuno)therapy. Despite the Program's recent inception, its integrated research platform has produced successful faculty recruitment, opened new opportunities for graduate education in cancer biology, considerably enhanced cancer focus, and developed extensive inter-programmatic and collaborative advances in the biology of metastasis, host-tumor cell crosstalk and immune modulation of tumor onset and progression. In terms of disease-relevance, TMM Program members are leading the development of a newly launched Ovarian Cancer Research Continuum Signature, a disease site-specific inter-programmatic initiative designed to merge basic, translational and patient oriented cancer research in a single scientific continuum. As of 2013, the TMM Program is expected to leverage a strong NCI funding base of $2.3 million, a total cancer-related peer-reviewed funding of $3.4 million (all direct costs), and currently lists 83 cancer-relevant publications, of which 29% are intra- and inter-programmatic collaborations, and 89% are inter-institutional collaborations. Building on these accomplishments, the TMM Program is on a steep, upward trajectory of research impact, scientific collaboration, and translational opportunities that leverage successful inter-institutional outreach partnerships as well as technological advances in key Shared Resources. During the next budget period, the TMM Program is ideally poised to significantly contribute to the Cancer Center's overarching mission in the continuum of cancer research by expanding scientific themes in the areas of metastatic competency and translational tumor immunology.

Public Health Relevance

The ability of tumor cells to thrive in vivo largely depends on the exploitation of cells and tissues that surround them, referred to as the microenvironment. Understanding how this immunosuppressive, proangiogenic, and pro-metastatic microenvironment is orchestrated to drive malignant progression may open new therapeutic prospects for patients with advanced and disseminated disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Tomescu, Costin; Tebas, Pablo; Montaner, Luis J (2017) IFN-? augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. AIDS :
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417
Veglia, Filippo; Gabrilovich, Dmitry I (2017) Dendritic cells in cancer: the role revisited. Curr Opin Immunol 45:43-51
Hoffman, Hunter; Rice, Cory; Skordalakes, Emmanuel (2017) Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes. J Biol Chem 292:4593-4601
Lu, Fang; Wiedmer, Andreas; Martin, Kayla A et al. (2017) Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol :
Karpel-Massler, Georg; Ishida, Chiaki Tsuge; Bianchetti, Elena et al. (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513-3526
Lynch, Shannon M; Mitra, Nandita; Ravichandran, Krithika et al. (2017) Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiol Biomarkers Prev 26:553-560
Perales-Puchalt, Alfredo; Svoronos, Nikolaos; Rutkowski, Melanie R et al. (2017) Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res 23:441-453
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Noguchi, Shuhei; Arakawa, Takahiro; Fukuda, Shiro et al. (2017) FANTOM5 CAGE profiles of human and mouse samples. Sci Data 4:170112

Showing the most recent 10 out of 685 publications